Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Are there biosimilars of enhertu t-dxd?

See the DrugPatentWatch profile for enhertu

Short answer: No. There are no approved biosimilars of Enhertu (trastuzumab deruxtecan) as of now.

What this means:
- Enhertu is an antibody–drug conjugate (ADC) consisting of trastuzumab linked to deruxtecan. Developing a biosimilar for an ADC is more complex than for a plain monoclonal antibody, and no such product has been approved yet.
- There are approved biosimilars to trastuzumab itself (the antibody part) from various manufacturers in different regions. These are not Enhertu biosimilars; they are biosimilars of Herceptin (trastuzumab) used for HER2-positive cancers.

If you’d like, I can look up the very latest status for a specific country or region and list any ongoing development programs or announced trials related to trastuzumab deruxtecan biosimilars.



Other Questions About Enhertu :

enhertu fda patent term Enhertu biosimilar? Enhertu price? What is the survival benefit of Enhertu in HER2-low breast cancer? Enhertu infusion? Enhertu patient expiry breast cancer loss of exclusivity? Daiichi enhertu patent expiration date?